0001415889-24-010709.txt : 20240411
0001415889-24-010709.hdr.sgml : 20240411
20240411180057
ACCESSION NUMBER: 0001415889-24-010709
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240409
FILED AS OF DATE: 20240411
DATE AS OF CHANGE: 20240411
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRAYZEL DAVID S.
CENTRAL INDEX KEY: 0001732786
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 24839554
MAIL ADDRESS:
STREET 1: C/O SURFACE ONCOLOGY
STREET 2: 50 HAMPSHIRE ST., 8TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4-04112024_100452.xml
X0508
4
2024-04-09
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001732786
GRAYZEL DAVID S.
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM
MA
02451
true
false
false
false
0
Common Stock
2024-04-09
4
S
0
11882
28.15
D
14502
I
By Atlas Venture Associates XII, L.P.
Common Stock
1784730
I
By Atlas Venture Fund XII, L.P.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.34 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares reported herein give effect to the pro rata distributions of shares by Atlas Venture Fund XII, L.P. ("Atlas Fund XII") for no additional consideration to its limited partners and its general partner, Atlas Venture Associates XII, L.P. ("AVA XII LP"), subsequent to the Reporting Person's last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distributions of such shares constituted only a change in the form of the Reporting Person's indirect ownership in such shares, the Reporting Person was not required to report the distributions pursuant to Section 16.
The shares are held directly by AVA XII LP. Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of the securities held by AVA XII LP, except to the extent of his pecuniary interest therein, if any.
The shares are held directly by Atlas Fund XII. The general partner of Atlas Fund XII is AVA XII LP. AVA XII LLC is the general partner of AVA XII LP. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of the securities held by Atlas Fund XII, except to the extent of his pecuniary interest therein, if any.
/s/ Ommer Chohan, Attorney-in-Fact
2024-04-11